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INTRODUCTION
Over the past decade, we have come to recognize that most peptic ulcers arise in the
setting of either H. pylori infection or the use of aspirin (ASA) or non-steroidal anti-
inflammatory drugs (NSAIDs). The pathogenetic mechanisms involved are still far from
clear; both H. pylori infection and NSAIDS have many effects on tissues and are associ-
ated with many clinical problems other than peptic ulcer.
Infection with H. pylori usually leads in time to chronic active gastritis ("type B" gas-
tritis or "superficial active gastritis") involving both the antrum and body ofthe stomach
and characterized by the presence of polymorphonuclear leukocytes in the tissue.
Organisms are visible on microscopy at the surface ofgastric glandular cells,just beneath
the mucus coat, adhering exclusively to columnar epithelial cells of the gastric mucosa.
Long-term infection is associated not only with chronic active gastritis and ulcers, but in
time, with gastric atrophy, gastric cancer, gastric MALT lymphoma, hypertrophic gas-
tropathy with protein-loosing enteropathy (Menetriere's Disease), and probably with the
condition known as "Epidemic Hypochlorhydria" [1].
In like manner, acetyl salicylic acid(ASA)b and nonsteroidal anti-inflammatory drugs
(NSAIDs) can cause a variety ofinjuries to any part ofthe gastrointestinal (GI) tract, but
their use, as discussed here, is particularly associated with erosive injury to the gastric
mucosa, often associated with "chemical" or "reactive" gastritis, characterized by foveo-
larhyperplasia, vasodilation, edema, relatively few inflammatory cells and the appearance
of muscle cells in the lamina propria [2, 3]. Both types ofgastritis are associated with an
increased risk of"peptic" ulceration [3], not only in the stomach but also in the duodenal
cap, which may or may not be similarly inflamed.
Over 25 years, as the incidence, prevalence and rates of hospitalization for peptic
ulcer disease have fallen, we have noted no overall decline in incidence rates for GI hem-
orrhage, bleeding ulcers or ulcer perforations; while these have become far less common
in those under 60 years ofage, in those over 60 they have risen rapidly, in some countries
to almost epidemic proportions.
We recognize that the burden of ulcer disease has shifted to the elderly, most ulcer
deaths occurring over age 75 years. Some of the increase in ulcer complications has been
linked to increasing use ofbothprescription and over-the-counter NSAIDs and aspirin-con-
taining products, due not only to their "ulcerogenic" or "erosive" effects on gastroduodenal
tissues and on the GI mucosa in general, but also to their potent anti-platelet effects (espe-
ciallyASA) thatincreasebleeding from avariety oflesions located anywhere in the GI tract
[4].
aTo whom allcorrespondence shouldbeaddressed: Denis M. McCarthy, M.D., VA Medical Center-
11 F, 2100 Ridgecrest Dr., S.E., Albuquerque, NM, 87108. Tel.: (505) 256-2801; Fax: (505) 256-
5751.
bAbbreviations: ASA, aspirin; NSAID, non-steroidal inflammatory drug.
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More recently, both hemorrhage and ulcer perforation have also been linked epi-
demiologically to the presence of H. pylori gastritis, with suggestions, based on small
studies, that eradication of infection significantly reduces the risk of subsequent hemor-
rhage from non-NSAID ulcers. Realization that many peptic ulcers were silent and sub-
clinical has prompted the suggestion that the high rate of GI complications, particularly
bleeding, surrounding the start of NSAID or ASA therapy in practice, was due to anti-
platelet effects ofthe drugs inpatients with underlying ulcerdisease, much ofitcausedby
H. pylori. This has raised many questions as to the need to eradicate H. pylori in ulcer
patients using ASA or NSAIDs, in the hope of influencing the main adverse outcome of
NSAID therapy, namely the hospitalization ofelderly patients for GI bleeding orperfora-
tion. Such outcomes have not been formally studied.
The failure to perform the appropriate outcome studies has stemmed from several
sources including: unwillingness to allow the relevant "high-risk" patients to enter clini-
cal trials; the fear that large numbers would be required to provide the statistical power to
resolve the issue, with consequent high costs incurred by those performing the trials; the
consequent search for a surrogate marker, such as an endoscopic lesion, that would accu-
rately predict the relevant outcome-an effort that has failed; and interests, largely com-
mercial, that opposed the identification of relevant high-risk subgroups requiring expen-
sive care, as a sensible alternative to subjecting the whole NSAID-consuming population
to expensive co-therapy orthe use ofexpensive but saferNSAIDs. The willingness ofgas-
troenterologists to perform lucrative endoscopy, however irrelevant, must also be recog-
nized as hindering the progress ofresearch in this area.
Thus, although there has been considerable interest in studying the possible interac-
tions of NSAIDs and H. pylori as risk factors for the development of serious gastroin-
testinal maladies requiring hospitalization, there has been a consistent failure to fund or
perform the kinds of studies needed to answer the clinically relevant questions. For this
reason, we are compelled to review a large number ofsmall studies, many published only
as abstracts, to try to discern in what directions the data point.
Additional problems stem from our lack ofunderstanding ofthe biology ofH. pylori,
particularly ofthose properties ofthe organism that contribute to the pathogenesis ofpep-
tic ulcers. While currently available serologic studies are useful in identifying subjects
who at some time have had exposure to H. pyloriinfection with consequent gastritis, sero-
logic tests tell us nothing about the current state ofthe patient, who by now may have lit-
tle gastritis. The severity ofthe gastritis cannot be predicted by easily available serologic
tests. Furthermore, only 10 to 15 percent ofthose infected everdevelop anulcer, the lesion
ofgreatest concern in studying interactions with NSAIDs. It is axiomatic that the absence
of an ulcer precludes the development ofulcer complications, but not the development of
bleeding from other gastrointestinal sites due to platelet dysfunction.
Problems surrounding the use of serologic diagnosis ofH. pylori in clinical research
have been discussed elsewhere [5-7] but include poor sensitivity, specificity and predic-
tive value forpeptic ulcer and some further reductions in these values associated with the
use ofNSAIDs [7]. Suffice it to say that studies relying solely upon serologic evidence of
H. pylori as arisk factor should be discounted as oflittle value, except that anegative test,
in the absence ofevidence to the contrary may generally beused todiscountH.pylori con-
tributing to an illness in an individual patient. Othertests, including breath tests, histologic
diagnosis, biopsy culture and various urease tests of gastric tissues or contents, all have
some limitations, especially in the area of thresholds below which negative tests may be
unreliable. For these reasons, in studying its interactions with NSAIDs or ASA, the best
studies confirm the diagnosis of H. pylori infection by at least two methods other than
serology. Since these drugs vary considerably in their platelet inhibiting and ulcerogenic
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properties, and in their in vitro effects on H. pylori [8], studies on H. pylori and NSAIDs
should exclude ASA, a compound that deserves separate study.
What then is the scope ofthis review? It is to examine a number ofindividual pieces
of a puzzle, using methodologies and underpinning assumptions that may or may not be
valid, in the hope of defining a basis for the design of effective future studies. These last
need to employ the techniques ofoutcomes research to quantitate the impact ofH. pylori-
NSAID and H. pylori-ASA interactions on hospitalization rates, morbidity and mortality
from adverse gastrointestinal events in those using NSAIDs.
H. PYLORI INFECTION AND DYSPEPTIC SYMPTOMS DUE TO NSAIDS
A large number ofstudies have examined the relationship between underlying chron-
ic active gastritis due to H. pylori and susceptibility to developing dyspeptic symptoms
while taking a variety ofNSAIDs [9, 10]. Many ofthese studies relied on serological char-
acterization of the patients; this, for reasons described above, confounds the problem.
Nevertheless, among a dozen major articles, eight concluded that underlying H. pylori
infection orgastritis increased the likelihood that apatientwoulddevelopdyspeptic symp-
toms when given either one or a succession of different NSAIDs; four studies failed to
find such an association. Overall, the emerging picture is that, at least in some cases, the
development of symptoms and their severity are attributable to underlying H. pylori gas-
tritis, although symptoms can also accompany NSAID use in the absence ofsuch (type B,
chronic active) gastritis. Stated another way, patients with H. pylori gastritis appear more
likely to develop troublesome dyspeptic symptoms when given NSAIDs.
NSAIDS, ASA AND H. PYLORI GASTRITIS
Much ofthe background to this discussion has been reviewedpreviously [9]. Forpre-
sent purposes, sufflce it to say that true inflammatory active gastritis, characterized by
polymorphonuclear neutrophilic infiltrates in the gastric mucosae ofNSAID users, is due
to co-incident H. pylori infection, and not to NSAIDs or ASA; these latter can cause
chemical gastritis, described above, in which mucosal neutrophils are rare. Both types of
gastritis are risk factors for ulcer disease [3] but rarely co-exist. It is well accepted that
NSAID therapy does not increase the incidence or prevalence of H. pylori infection or
gastritis, or the susceptibility of the patient to acquiring H. pylori infection de novo. The
prevalence of H. pylori infection/gastritis may, if anything, be somewhat lower in all
NSAID users [9], especially in studies that include ASA as an NSAID. When full-dose
ASA therapy is in use, it is distinctly uncommon to find H. pylori in biopsies, suggesting
either that ASA therapy, by destroying the mucus layer, unfavorably alters the habitat or
"biologic niche" in which H. pylori survives or that the demonstrated in vitro activity of
ASA against H. pylori also occurs in vivo [8, 9].
The converse ofthe above relationship is less clear and less well examined. It remains
a possibility that underlying H. pylori gastritis alters the host susceptibility to NSAID
injury, not as reflected by altered incidence orprevalence, but as reflected in the course and
severity of the gastritis. Few studies have examined the issue of severity carefully in
prospective studies with repeated biopsies ofthe patients. Those that have attempted to do
so for the most part evaluated the effect of NSAIDs as a categorical variable and have
ignored quantitative parameters such as type and dose ofNSAID, duration ofexposure and
follow-up, type of patient studied, co-therapy with potentially protective drugs like
antacids, sucralfate, H2-antagonists, proton pump inhibitors, bismuthcompounds, etc., and
have lumped together those with any evidence of exposure to H. pylori with the critical
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sub-group ofthose who had H. pylori and peptic ulcer prior to the onset ofNSAID thera-
py. Only this last group provides any indication of the existence ofthe host and H. pylori
virulence factors most relevant to questions ofinteraction clinically.
The interactions ofH. pyloriandchemical gastritis may be complex, and some effects
may cancel out or oppose other effects [10]. For instance, at least two studies have shown
that gastric mucosal and lumenal concentrations of prostaglandin E2 are higher in H.
pylori infected patients than in normals [11, 12]. If the mechanisms by which ASA and
NSAIDs lead to chemical gastritis in healthy mucosa involve inhibition ofprostaglandin
synthesis, then it is possible that H. pylori infection might be protective, by countering
such inhibitory effects on prostaglandin synthesis.
In fact, a recent study in "normal" volunteers supports such a hypothesis [13]. After
an initial endoscopy to establish the baseline state of their gastric antral mucosal histol-
ogy, 19 patients were given naproxen 1 g/d for one week, and then re-endoscoped and re-
biopsied to examine the incidence of de novo chemical gastritis [13]. Among eight sub-
jects with H. pylori infection, none developed chemical gastritis, compared to five cases
developing among 11 patients who were free of H. pylori infection. While the numbers
are small, they support the notion that H. pylori may protect against chemical gastritis.
Unfortunately, the study did not quantitate whether or not active gastritis changed in the
infected group.
In the same way, treating ASA consumption as a categorical variable, ignores sever-
al important considerations, such as dose-response effects ofASA on the gastric mucosa
with, for example, adaptation at low dosage overwhelmed at high dosage, and dose-
response effects on platelets, which could increase the risk ofbleeding while limiting the
survival ofH. pylori on the mucosal surface.
Despite several studies claiming that NSAIDs had no effect on chronic active gastri-
tis, there are some indications that this warrants more careful study. Early observations in
arthritis patients studied before and afterNSAID therapy showed significant worsening of
active gastritis during therapy with sulindac, with a similar trend observed in fourofseven
patients treated with indomethacin [14]; based on the histology, these patients were almost
certainly infected with H. pylori although this was not determined in 1982. A very care-
ful double-blind study [15], which performed endoscopy and obtained biopsies at base-
line and four weeks after commencing therapy with either tenoxicam 20 mg/d or
diclofenac 100 mg/d, quantitated endoscopic injury scores, histopathologic changes
(severity of gastritis) and intensity of mucosal colonization with H. pylori. The study
found that, ofthose with no or mild active gastritis due to H. pylori at baseline, only one
of 22 treated for four weeks with an NSAID progressed to severe gastritis. However,
among 14 patients with moderate gastritis at baseline, severe gastritis developed in five,
and one developed a duodenal ulcer (p < .02). Similarly, in another study in which 51 sub-
jects were randomized to treatment with placebo, meloxicam 5 mg/d or piroxicam 20
mg/d (double-blind) for 28 days, there was a strong positive association between H. pylori
infection and the severity of mucosal damage (Lanza scale) or with increases in serum
concentrations ofpepsinogen A and C (markers ofmucosal damage) [16].
While the only other studies that prospectively studied patients present before and
after NSAID therapy failed to document such an effect ofNSAIDs on the severity ofgas-
tritis [11, 17], both studies had features that militated against conclusiveness. In the first
study [17], normal volunteers were treated foronly seven days, and assessments ofeffects
were confined to recording endoscopic scores for mucosal hemorrhage (not a feature of
active gastritis); the diagnosis ofH. pylori was serologic, and no histology was obtained
before or after therapy.
In the second study, normal volunteers were again employed: 52 were randomized to
placebo (17), naproxen (18), and etodolac (17). However, the highest percentage of H.
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pylori infected patients (59 percent) received etodolac, a very non-injurious NSAID, the
second highest group (47 percent) received placebo, and only 45 percent ofthe 18 receiv-
ing naproxen, another comparatively safe NSAID [18], were infected. This study lacked
the statistical power to accept orreject any hypothesis with confidence. Other studies that
failed to show NSAID effects on severity of active gastritis either did not have repeated
biopsies in the same subjects before and after drug, or lacked careful quantitative
microscopy ofdamage or inflammation. Thus, the present data favor the notion that ther-
apy with potent NSAIDs may increase the severity of gastritis due to H. pylori over the
course offour weeks. The importance ofthis is that severity and activity ofgastritis have
been shown to be greater in H. pylori subjects with ulcers, particularly duodenal ulcers,
than in infected subjects without ulcers [19]. Another study also noted that antral gastritis
was predictive ofdeveloping ulcers during NSAID therapy [20].
As mentioned previously, both "chemical" or "reactive" gastritis appear to predispose
to ulcerdevelopment [3]. Many pathologists are much better atrecognizing neutrophils in
the mucosa than at finding H. pylori organisms, particularly in patients who have been
treated with anti-ulcer or anti-microbial drugs. The presence of neutrophils is also com-
mon to both chemical and active gastritis. A recent study [21] has shown that the density
of neutrophils per high-powered field in antral biopsies, was strongly correlated with the
risk ofulcer development during NSAID therapy. However, the risk could be substantial-
ly reduced by co-therapy with famotidine 20 mg or 40 mg b.i.d.. This finding, if substan-
tiated in other studies, could prove to be very useful clinically in identifying which
patients using NSAIDS need special attention to preventing ulcers and their complica-
tions.
NSAIDS, ASA, H. PYLORIAND ULCERS
NSAID ulcers and infection status.
Over the past decade, a growing number of studies suggests that among long-term
users ofNSAIDs, the occurrence of ulcer is statistically significantly higher in H. pylori
infected than in uninfected patients: these data are summarized in Table 1. If these are
averaged, almost three times as many lesions are found in H. pylori-infected subjects.
Some studies have failed to confirm this observation [28, 29], but the first study selected
only symptomatic gastric ulcer patients undergoing endoscopy, rather than prospectively
studying a cohort of patients taking NSAIDs [28], and the second depended solely on
serologic diagnosis ofH. pylori status, and also had exclusion criteria that would bias the
study [29]. A third study, based on endoscopic studies and strict criteria for the diagnosis
ofH. pylori gastritis, showed, among 75 NSAID users 13 ulcers, 11 of which were in H.
pylori-infected patients. Thus, overall data indicate that the majority of ulcers found in
NSAID users are in those infected with H. pylori [30].
Two studies, published only in abstracts, [31, 32] have drawn attention to the high
percentage ofgastric ulcers in NSAID users that were associated with H. pylori infection:
only 11 percent of 161 patients [31] and 14 percent of 26 patients [32] were uninfected,
emphasizing that both factors are present in the majority ofgastric ulcers associated with
NSAID use. The study by Publig (Table 1) found that 81.5 percent of those with gastric
ulcers on NSAIDs were also infected with H. pylori [24]. In an older but similar study of
107 patients undergoing endoscopy, but relying on serologic diagnosis of H. pylori, 25
percent of gastric ulcers were solely related to NSAID use, without H. pylori infection,
but, despite NSAID use among 14 duodenal ulcers, none occurred in an uninfected sub-
ject [33].
105McCarthy: H. pylori andNSAIDs
Table 1. Occurrence ofpeptic ulcers and erosions (one study) in patients with and
without H. pyloni on long-term NSAIDs.
Author Hp +ve Hp -ve
Year, [Ref.] (%) (%) p value
Annstrong and Blower GU 31 15 p < .02
1987 [22]
Taha et al. GU/DU 48 22 p <.01
1992 [3]
Heresbach et al. GU/DU 37 11 p < .02
1992 [23]
Publig et al. GU/DU 83 17 P < .02
1994 [24]
Taha et al. Ulcers 40 15 p < .01
1995 [25] Erosions 60 25 p < .05
Ekstrom et al. GU/DU 26 7 p < .02
1995 [26]
Bianchi Porro [27] GU/DU 70 30 p < .01
Two ofthe studies listed in Table 1, that ofEkstrom et al., 1995 [26], and Taha et al.,
1995 [25], are prospective studies and yield data on the incidence ofnew ulcers after ini-
tiation ofNSAID therapy as related toH. pylori status. Both provide only combined totals
of gastric and duodenal ulcers, not broken down by site. Nevertheless, 16.7 percent of
patients developed an ulcer in three months on NSAIDs in the Scandinavian study, lesions
occurring almostfourtimes morefrequently inH. pylori-infected patients [26]. The small-
er ofthe two studies showed, during six months ofNSAID therapy, that ulcers developed
in 40 percent (12) ofH. pylori-infected patients compared to 15 percent (3) in uninfected
patients (p < .01) [25].
Does H. pylori gastritis affect the response to low-dose aspirin therapy?
A nested case-control study of sera of 166 of22,071 male physicians taking 325 mg.
ASA per day [34] who developed ulcers were compared with sera from age and treatment
matched controls. In patients taking ASA, sera of significantly more patients with ulcers
were positive for anti-bodies to H. pylori, (HP+), 63.8 percent, compared to those without
ulcers, 51 percent. A smaller study fromTurkey [35] prospectively took 32 patients begin-
ning therapy with enteric coatedASA, 300mg/d and randomized them to receive initial H.
pylori eradication therapy with omeprazole and amoxicillin, or placebo eradication; at
endoscopy those with H. pylori by CLO test and histology, had higher base-line endo-
scopically evaluated gastric injury scores than those without infection. Following ASA
therapy, scores rose in both infected and post-eradication-therapy patients, but final injury
scores were significantly higher in those who remained infected (1.94 + 0.33) than in
those who were infection free (0.80 + 0.22, p < .05). Histologic grading of gastritis was
notperformed. In the group who remained infected, two of 17 developed ulcers, compared
to none of 15 patients free of infection (NS). This issue warrants further study.
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Does eradication ofH. pylori reduce the occurrence ofNSAID-associated ulcers?
The cleanest study [36], involving 92 patients with musculoskeletal pain and in need
of NSAID therapy, randomized all patients to either naproxen 750 mg/d, or one week of
triple therapy with tetracycline, metronidazole and bismuth, followed by naproxen 750
mg/day. After two months, among evaluable patients, three of 45 (6.7 percent) patients
given triple therapy and 12 of 47 treated with naproxen alone (25 percent) developed
ulcers (p = .014): two of the three were failures of eradication with, thus, only one ulcer
in an uninfected patient. About half of the ulcers bled or became symptomatic in the
naproxen treated group, compared to none in those who received triple therapy with erad-
ication.
A second study from Poland [37] examined the ulcer recurrence rate over the eight
months following initial treatment-to-healing with various drug regimens: only those
treated with omeprazole, amoxicillin and metronidazole triple therapy showed no diminu-
tion in healing (92 percent) between one and eight months after eradication, despite con-
tinued NSAID therapy.
A third rather complicated study examined the role ofH. pylori in ulcer healing dur-
ing omeprazole therapy orin recurrence following eradication ofinfection [27]. The study
essentially failed to find a difference in ulcer recurrence rates between those in whom H.
pylori was eradicated and those in whom infection persisted, although numbers were
small. However, no information of any kind is given as to what NSAIDs were used or in
what dosage. Furthermore, in some patients, post-eradication status ofH. pylori infection
was determined after they had been allowed alternative therapy such as sucralfate, which
may notbe devoid ofH. pylori suppressive activity. Finally, based on alarge Finnish study
of cure of gastric ulcer associated with eradication of H. pylori infection, Seppala [38]
commented that "aftereradication ulcerrecurrence was very rare, even whenpatients con-
tinued to take NSAIDs," but gave us no actual data. On balance, therefore, it appears like-
ly that H. pylori eradication lowers the risk of ulcer recurrence during continued NSAID
therapy, but more data are needed.
NSAIDS, H. PYLORI GASTRITIS AND GASTROINTESTINAL BLEEDING
In this area, few data are available beyond those found in abstracts. Several prelimi-
nary reports have found that in patients notusing NSAIDs, H. pyloriinfectedpatients pre-
senting with acute peptic ulcer bleeding have benefited strongly from eradication therapy
asjudged by reductions in recurrences ofboth ulcers and bleeding. This would appear to
establish that H. pylori is a risk-factor for gastrointestinal hemorrhage, largely from gas-
troduodenal lesions.
To what extent this applies to patients who bleed in the context ofNSAID use is much
less clear. It is apparent that patients using NSAIDs can bleed from ulcers or other GI
lesions, in the complete absence ofH. pylori infection. Thus, ASA and NSAIDs are both
independentriskfactors forulcerbleeding andforGIbleeding in general, less than 50per-
cent of which comes from ulcers, and some ofwhich comes from the lower GI tract.
At least five groups have published abstracts [39-43] in which NSAIDs andH. pylori,
studied in the same patient groups, emerge as independent risk factors for bleeding, but
allegedly show no interaction. The fact that risk factors are independent does not exclude
the possibility that they are also additive or interactive in complex ways. The largest of
these studies [39] had 128 patients and 128 controls. The numbers needed to reject inter-
action with 95 percent confidence are an order ofmagnitude higher than this, so that the
claims for "no interaction" must be taken with reservation.
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One Danish study, published only in abstract form, seems to cast doubt on the
absence ofinteraction. A group of 132 consecutive patients with NSAID-related bleeding
peptic ulcers were matched by age, sex and other factors in a case-control study, with sim-
ilar NSAID users who had not bled. Based on odds ratios, H. pylori emerged as increas-
ing the risks of NSAID-associated bleeding about two-fold. My main reservation about
this study is thatASA was included among NSAIDS, and it is possible that differences in
the numbers ofASA users, or the doses ofASA consumed, were not the same in bleeders
and controls. Such an imbalance could alter the odds ratio appreciably. In the meantime,
it intuitively seems reasonable to argue that since both NSAIDs and H. pylori are inde-
pendent risk factors for bleeding ulcer, H. pylori should be treated to eradication in elder-
ly NSAID users, who have high usage of NSAIDs, a high prevalence of H. pylori infec-
tion and gastritis, and a high prevalence of peptic ulcers, many of which are clinically
silent. This issue remains unresolved. Seropositive patients with ulcers or a history ofpep-
tic ulcer or bleeding should certainly receive eradication therapy before starting
NSAID/ASA therapy.
NSAIDS, H. PYLORI INFECTION AND ULCER PERFORATION
From epidemiologic studies, it is apparent that ulcer perforation is increasingly com-
mon in elderly subjects. In the United Kingdom, this has appeared to be linked to a rise in
the consumption of NSAIDs by the elderly, but in Scandinavia, Germany, Australia and
the United States, this linkage is far less clear, and not more than 20 to 30 percent of the
increase is attributable to NSAID use. Much of the increase must be attributed to other
factors, among which is smoking. Nevertheless, a group exists in which perforation seems
linked to NSAID orASA use, and it is in this group that the question arises as to whether
or not H. pylori infection or gastritis poses an additional risk that could be abolished by
eradicating the infection. Because perforation is so much less common than bleeding,
progress has been slow in this area. From animal studies, NSAIDs vary greatly in the like-
lihood of perforation associated with their oral use. Only parenteral use of Ketorolac is
commonly associated with perforation, and I know of no data on the prevalence of H.
pylori in affected versus unaffected patients. A single clinical study by Reinbach in 1993
[45] suggestedthatthe prevalence ofH. pylori did not differ significantly between patients
perforating duodenal ulcers during NSAID therapy, regular NSAID users without perfo-
ration and matched hospital controls. The question remains open at the present time.
SUMMARY
1. H. pylori gastritis appears to increase the likelihood of developing dys-
peptic symptoms on NSAID therapy.
2. There is preliminary evidence that the histologic severity of H. pylori
gastritis may be adversely affected by NSAID therapy, with a conse-
quent increase in the risk of developing a peptic ulcer, possibly with
complications. Whether this results from an effect on the inflammatory
process or results from a quantitative increase in H. pylori colonization
is unknown. In these respects, ASA may differ from other NSAIDs.
3. Ulcers are more likely to develop during the course of NSAID therapy
in those infected with H. pylori; eradication of the infection reduces
ulcer recurrence in the face of continued NSAID therapy, and it seems
likely that this must reduce but not abolish the risk of GI bleeding in
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those using NSAIDs. Eradication also reduces the damage (and possi-
bly risks) of low-dose aspirin therapy.
4. While H. pylori and NSAID use are independent risk factors for GI
bleeding, whether or not they are interactive remains unresolved.
5. The effect of H. pylori infection on the risk of perforation during
NSAID therapy, or conversely, the contribution of NSAID therapy to
the risk of perforation in H. pylori-infected subjects, is also unclear at
the present time.
6. Only large outcome studies of accurately diagnosed patients (with
regard to H. pylori gastritis), and with much more specific detail as to
the type ofNSAID, dose and duration oftherapy, employing only well-
defined end-points, such as significant hemorrhage, perforation or
death, and avoiding all surrogate markers short ofthese end points can
hope to unravel this tangled web.
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